BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Boehringer Ingelheim
Fish and Richardson

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,599,353

« Back to Dashboard

Summary for Patent: 4,599,353

Title: Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
Abstract:Ocular hypertension and glaucoma can be effectively controlled in primates through topical application of an effective amount of an eicosanoid or an eicosanoid derivative to the surface of an afflicted eye. Eicosanoids, particularly the prostaglandins PGE.sub.2 and PGF.sub.2.alpha., and derivatives thereof, have been found effective in quantities less than about 1000 .mu.g per eye. Ophthalmic compositions containing C.sub.1 to C.sub.5 alkyl esters of PGF.sub.2.alpha. are presently preferred for use in treating ocular hypertension and glaucoma in primates, including man.
Inventor(s): Bito; Laszlo Z. (New York, NY)
Assignee: The Trustees of Columbia University in the City of New York (New York, NY)
Application Number:06/374,165
Patent Claim Types:
see list of patent claims
Use; Composition;

No matches for this query

International Patent Family for Patent: 4,599,353

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia560189► Subscribe
Canada1208560► Subscribe
Germany3369068► Subscribe
Denmark195083► Subscribe
European Patent Office0093380► Subscribe
JapanH0468288► Subscribe
JapanS591418► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus